P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis: a Danish population-based regional cohort and qualitative implementation study.
Tanja Schjødt Jørgensen,Jens Jørgen Lykkegaard,Annette Hansen,Heidi Morsø Schrøder,Betina Stampe,Anne Marie Tetsche Sweeney,Bente Appel Esbensen,Bianca Bech,Katja Christensen,Ellen Friis-Mikkelsen,Henrik Røgind,Tine Lundbak,Peter C. Taylor,Ingemar F Petersson,Eva Ejlersen Wæhrens,Jakob Kjellberg,Henrik Gudbergsen,Lars Erik Kristensen +17 more
TL;DR: The aim of this study is to compare medical and patient evaluated impact of the traditional settlement and financing production (DAGS) controlled healthcare setting with a value-based and patient-centred adjunctive to standard care.
Journal Article
Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients
José María Álvaro-Gracia,Juan Angel Jover,Rosario García-Vicuña,Luis Carreño,Arnald Alonso,Sara Marsal,Francisco J. Blanco,Víctor M. Martínez-Taboada,Peter C. Taylor,Federico Díaz-González,L. Dorrego +10 more
Journal ArticleDOI
How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA
TL;DR: Overall, abatacept had a relatively more-acceptable safety and tolerability profile compared to infliximab, which was a similar efficacy for both drugs; however, in the 6-month treatment extension period, outcomes of efficacy differed in favor of abatACEpt.
Patent
Methods and system for determining the disease status of a subject
TL;DR: In this article, a method of determining the osteoarthritis, inflammatory arthritis or joint injury status in a subject, and a panel of test biomarkers for use in determining same is disclosed.
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. [version 2; referees: 2 approved]
Jagdeep Nanchahal,Catherine Ball,Jennifer B. Swettenham,Susan J Dutton,Vicki S Barber,Judith Black,Bethan Copsey,Melina Dritsaki,Peter C. Taylor,Alastair Gray,Marc Feldmann,Sarah E Lamb +11 more
TL;DR: Using excised diseased and control human tissue, it was found that immune cells interspersed amongst the myofibroblasts secrete cytokines, and the clinically approved anti-TNF agents led to inhibition of the my ofibroblast phenotype in vitro.